Tyrogenex to Present at 18th Annual BIO CEO & Investor Conference™

-Tyrogenex Presentation Scheduled for 3:15 PM EST on Monday February 8, 2016-

Feb 03, 2016, 10:21 ET from Tyrogenex

NEEDHAM, Mass., and PALM BEACH GARDENS, Fla., Feb. 3, 2016 /PRNewswire/ -- Tyrogenex, a privately held biopharmaceutical company, today announced it will present a company update at the Waldorf Astoria, New York, NY.

Tyrogenex CEO Michael D. Webb will present a company update on February 8, at 3:15 pm EST in the Park North Room.

Tyrogenex is developing X-82, an orally-administered dual vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor, for wet age-related macular degeneration (wet AMD) and solid tumors.

For wet AMD, one of the leading causes of blindness for people over the age of 50 that affects more than 1.5 million Americans, the company is enrolling patients in the APEX phase 2 trial for the treatment of wet AMD.

BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The mission is to support industry-wide success by presenting a broad and unbiased view of investment opportunities

About Tyrogenex
Tyrogenex is a biopharmaceutical company focused on improving the lives of patients with wet AMD and solid tumors by discovering medicines to help provide additional treatment options. Tyrogenex's lead compound is X-82. For more information, visit www.tyrogenex.com

About X-82
Tyrogenex's lead compound is X-82.  X-82 inhibits both VEGF and PDGFR. Tyrogenex believes X-82 targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis and inflammation.  X-82 is currently being evaluated for wet AMD and solid tumors.

About Wet AMD
AMD is the leading cause of blindness for people over the age of 50 in the United States and Europe. There are two forms of the disease, namely "dry" and "wet" AMD. Wet AMD is characterized by the growth of new blood vessels into the central region of the retina. These new and abnormal blood vessels cause severe central vision loss due to retinal damage caused by leakage of the blood vessels and subsequent scar formation.

Forward-Looking Statements
This press release contains forward-looking statements that are based on company management's current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.

Corporate Contact:
Teri Swift
Tyrogenex Corporate Communications
(561) 406-9705
teri@tyrogenex.com

Logo - http://photos.prnewswire.com/prnh/20151113/287174LOGO

SOURCE Tyrogenex



RELATED LINKS

http://www.tyrogenex.com